



(51) International Patent Classification:

C07D 403/12 (2006.01) *A61K 31/4155* (2006.01)
C07D 231/38 (2006.01) *A61P 11/06* (2006.01)
C07D 401/12 (2006.01) *A61P 37/08* (2006.01)

(21) International Application Number:

PCT/US2014/056024

(22) International Filing Date:

17 September 2014 (17.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/879,585 18 September 2013 (18.09.2013) US

(71) Applicant: **AXIKIN PHARMACEUTICALS, INC.**
 [US/US]; 4940 Carroll Canyon Road, Suite 100, San
 Diego, CA 92121 (US).

(72) Inventors: **LY, Tai, Wei**; 10824 Caminito Colorado, San
 Diego, CA 92131 (US). **RAAUM, Erik, Dean**; 4020 N.
 Teewinot Rd., Teton Village, WY 83025 (US).

(74) Agents: **RIEGER, Dale, L.** et al.; Jones Day, 222 East
 41st Street, New York, NY 10017-6702 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS



(IA)

(57) Abstract: Provided herein are pharmaceutically accept-
 able salts of 3,5-diaminopyrazoles, for example, pharmaceut-
 ically acceptable salts of compounds of Formula (IA), that are
 useful for modulating regulated-in-COPD kinase activity, and
 pharmaceutical compositions thereof. Also provided herein
 are methods of their use for treating, preventing, or ameliorat-
 ing one or more symptoms of a RC kinase-mediated disorder,
 disease, or condition.

